Skip to content

VHCP Management III, LLC

Follow

13F filer, CIK 1738053, New York, NY

VHCP Management III, LLC reported $137,578,000 across 15 holdings for the quarter ended 2018-12-31, in a 13F-HR filed 2019-02-13. Its ten largest share positions make up 93.9% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0000950123-19-001655

Period
2018-12-31
Reported value
$138M
Holdings
15
Top 10 weight
93.9%
New
5
Sold out
3

Stakes and trades reported after 2018-12-31

13D, 13G and Form 4 filings by this filer's group, dated after the 13F period, on securities the quarter does not hold as shares.

  • OKUR ONKURE THERAPEUTICS INC: 13G 2,309,559 shares, 5.7% of the class, 13G filed 2026-11-20, 0001231919-26-001621Timeline
    Accepted , ingested
  • ENTX ENTERA BIO LTD: 13G 8,861,763 shares, 5.1% of the class, 13G filed 2026-10-30, 0001738048-26-000079Timeline
    Accepted , ingested
  • LYCA LYCIA THERAPEUTICS INC: 13G 6,850,237 shares, 11.9% of the class, 13G filed 2026-10-30, 0001738048-26-000077Timeline
    Accepted , ingested
  • FLSC FRAZIER LIFE SCIENCES ACQ-A: 13G 700,000 shares, 9% of the class, 13G filed 2026-10-27, 0001738048-26-000075Timeline
    Accepted , ingested
  • XFOR X4 PHARMACEUTICALS INC: 13G/A 7,644,072 shares, 7.6% of the class, 13G/A filed 2026-11-16, 0001738048-26-000100Timeline
    Accepted , ingested
  • VOR VOR BIOPHARMA INC: 13G/A 6,443,619 shares, 9.9% of the class, 13G/A filed 2026-11-16, 0001738048-26-000098Timeline
    Accepted , ingested
  • KRRO KORRO BIO INC: 13G/A 1,474,162 shares, 9.9% of the class, 13G/A filed 2026-11-16, 0001738048-26-000096Timeline
    Accepted , ingested
  • JBIO JADE BIOSCIENCES INC: 13G/A 3,858,984 shares, 5.9% of the class, 13G/A filed 2026-11-16, 0001738048-26-000094Timeline
    Accepted , ingested
  • HELP HELUS PHARMA INC: 13G/A 2,688,175 shares, 3.5% of the class, 13G/A filed 2026-11-16, 0001738048-26-000092Timeline
    Accepted , ingested
  • CBIO CRESCENT BIOPHARMA INC.: 13G/A 2,228,641 shares, 5.9% of the class, 13G/A filed 2026-11-16, 0001738048-26-000090Timeline
    Accepted , ingested
  • ACHV ACHIEVE LIFE SCIENCE INC: 13G/A 5,502,064 shares, 5.2% of the class, 13G/A filed 2026-11-16, 0001738048-26-000088Timeline
    Accepted , ingested

Largest buys vs the previous quarter

SecurityShares changeApprox. value
ORCHARD THERAPEUTICS PLCnew+1,041,515$16.4M
RA PHARMACEUTICALS INCnew+594,713$10.8M
DBV TECHNOLOGIES S Anew+636,800$4.09M
PTGXnew+423,176$2.85M
YUMANITY THERAPEUTICS INCnew+848,610$2.75M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
ENDOCYTE INCexited-600,000-$10.7M
APLSexited-50,290-$894K
CHEMOCENTRYX INCexited-39,036-$493K

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q4 2018

Share positions as resolved from 13F-HR 0000950123-19-001655, largest first. % of portfolio is the value over $137,578,000, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
KALVKALVISTA PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2017Q1: restricted; 2017Q2: restricted; 2017Q3: restricted; 2017Q4: restricted; 2018Q1: not loaded; 2018Q2: not loaded; 2018Q3: 1,284,931 shares; 2018Q4: 1,284,931 shares 1,284,931$25.4M18.45%0Timeline
BCRXBIOCRYST PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2017Q1: restricted; 2017Q2: restricted; 2017Q3: restricted; 2017Q4: restricted; 2018Q1: not loaded; 2018Q2: not loaded; 2018Q3: 3,061,091 shares; 2018Q4: 3,061,091 shares 3,061,091$24.7M17.96%0Timeline
ORCHARD THERAPEUTICS PLCORCHARD THERAPEUTICS PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2017Q1: restricted; 2017Q2: restricted; 2017Q3: restricted; 2017Q4: restricted; 2018Q1: not loaded; 2018Q2: not loaded; 2018Q3: not reported; 2018Q4: 1,041,515 shares 1,041,515$16.4M11.91%new
TRICIDA INCTRICIDA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2017Q1: restricted; 2017Q2: restricted; 2017Q3: restricted; 2017Q4: restricted; 2018Q1: not loaded; 2018Q2: not loaded; 2018Q3: 650,585 shares; 2018Q4: 650,585 shares 650,585$15.3M11.15%0
ObsEva SAObsEva SAQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2017Q1: restricted; 2017Q2: restricted; 2017Q3: restricted; 2017Q4: restricted; 2018Q1: not loaded; 2018Q2: not loaded; 2018Q3: 1,159,789 shares; 2018Q4: 1,159,789 shares 1,159,789$14.7M10.67%0
RA PHARMACEUTICALS INCRA PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2017Q1: restricted; 2017Q2: restricted; 2017Q3: restricted; 2017Q4: restricted; 2018Q1: not loaded; 2018Q2: not loaded; 2018Q3: not reported; 2018Q4: 594,713 shares 594,713$10.8M7.87%new
KINIKSA PHARMACEUTICALS LTDKINIKSA PHARMACEUTICALS LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2017Q1: restricted; 2017Q2: restricted; 2017Q3: restricted; 2017Q4: restricted; 2018Q1: not loaded; 2018Q2: not loaded; 2018Q3: 327,777 shares; 2018Q4: 327,777 shares 327,777$9.21M6.69%0
KADMON HOLDINGS INCKADMON HOLDINGS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2017Q1: restricted; 2017Q2: restricted; 2017Q3: restricted; 2017Q4: restricted; 2018Q1: not loaded; 2018Q2: not loaded; 2018Q3: 2,388,572 shares; 2018Q4: 2,388,572 shares 2,388,572$4.97M3.61%0
DBV TECHNOLOGIES S ADBV TECHNOLOGIES S AQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2017Q1: restricted; 2017Q2: restricted; 2017Q3: restricted; 2017Q4: restricted; 2018Q1: not loaded; 2018Q2: not loaded; 2018Q3: not reported; 2018Q4: 636,800 shares 636,800$4.09M2.97%new
MARINUS PHARMACEUTICALS INCMARINUS PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2017Q1: restricted; 2017Q2: restricted; 2017Q3: restricted; 2017Q4: restricted; 2018Q1: not loaded; 2018Q2: not loaded; 2018Q3: 672,271 shares; 2018Q4: 1,258,964 shares 1,258,964$3.61M2.63%+586,693
PTGXPROTAGONIST THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2017Q1: restricted; 2017Q2: restricted; 2017Q3: restricted; 2017Q4: restricted; 2018Q1: not loaded; 2018Q2: not loaded; 2018Q3: not reported; 2018Q4: 423,176 shares 423,176$2.85M2.07%newTimeline
YUMANITY THERAPEUTICS INCYUMANITY THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2017Q1: restricted; 2017Q2: restricted; 2017Q3: restricted; 2017Q4: restricted; 2018Q1: not loaded; 2018Q2: not loaded; 2018Q3: not reported; 2018Q4: 848,610 shares 848,610$2.75M2%new
BELLEROPHON THERAPEUTICS INCBELLEROPHON THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2017Q1: restricted; 2017Q2: restricted; 2017Q3: restricted; 2017Q4: restricted; 2018Q1: not loaded; 2018Q2: not loaded; 2018Q3: 2,274,370 shares; 2018Q4: 2,274,370 shares 2,274,370$1.82M1.33%0
GEMPHIRE THERAPEUTICS INCGEMPHIRE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2017Q1: restricted; 2017Q2: restricted; 2017Q3: restricted; 2017Q4: restricted; 2018Q1: not loaded; 2018Q2: not loaded; 2018Q3: 869,538 shares; 2018Q4: 869,538 shares 869,538$704K0.51%0
CONSTELLATION PHARMACEUTICALCONSTELLATION PHARMACEUTICALQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2017Q1: restricted; 2017Q2: restricted; 2017Q3: restricted; 2017Q4: restricted; 2018Q1: not loaded; 2018Q2: not loaded; 2018Q3: 66,667 shares; 2018Q4: 66,667 shares 66,667$267K0.19%0

Sold out in Q4 2018

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
ENDOCYTE INCENDOCYTE INC600,000$10.7Mshares
APLSAPELLIS PHARMACEUTICALS INC50,290$894Kshares
CHEMOCENTRYX INCCHEMOCENTRYX INC39,036$493Kshares

How Q4 2018 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0000950123-19-001655 base2019-02-13acceptance time not in the bulk data set